Text Size
201 studies found for:    "Expanded Access" [STUDY-TYPES]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Unknown † Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Paclitaxel Cisplatin
22 Available Compassionate Use of the Becker Expander/Breast Implant
Condition: Breast Reconstruction
Interventions: Device: Becker 50 Expander/Breast implant;   Device: Becker 25 Expander/Breast implant
23 Available To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia
Condition: Arrhythmia
Intervention: Other: MCG
24 Available Compassionate Use of Stiripentol in Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: Stiripentol
25 No longer available Erwinase Master Treatment Protocol
Conditions: Leukemia, Acute Lymphoblastic;   Acute Lymphoid Leukemia
Intervention: Drug: Erwinia L-asparaginase
26 Temporarily not available Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: R(+) pramipexole dihydrochloride monohydrate
27 No longer available A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
Condition: HIV
Intervention: Drug: Maraviroc
28 Available A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome
Conditions: Diabetes;   CVD
Intervention: Drug: Rosuvastatin,SFC fenofibrate
29 Temporarily not available Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
Condition: Infection Due to Resistant Organism
Intervention: Drug: Arbekacin Sulfate
30 Available Use of Eylea for the Treatment of an Optic Nerve Hemangioma
Condition: Retinal Hemangioma
Intervention: Drug: Aflibercept
31 Available Effects of High-intensity Interval Training in Patients in Hemodialysis
Conditions: Chronic Renal Disease;   Hemodialysis
Intervention: Other: exercise
32 No longer available Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: AMN107
33 Unknown † Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 diaminopyridine
34 Available A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
Condition: Liver Cancer
Intervention: Device: Theraspheres
35 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
36 Available Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD
Conditions: Graft vs Host Disease;   Graft-Versus-Host Disease
Intervention: Drug: Prochymal®
37 Available An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Conditions: Malignant Solid Tumour;   Breast Cancer;   Ovarian Cancer;   Colorectal Cancer
Intervention: Drug: NKTR-102
38 Available Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
Condition: Post-transplant Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin;   Drug: Pegylated Interferon
39 No longer available Buphenyl Therapy for Byler's Disease
Condition: Byler Disease
Intervention: Drug: Buphenyl
40 Approved for marketing Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease
Conditions: Glycogen Storage Disease Type II;   Glycogenosis 2
Intervention: Biological: alglucosidase alfa
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years